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Background: Pulmonary hypertension (PH) is a complication of chronic obstructive pulmonary disease (COPD).
This study examined genetic variations in mediators of vascular remodelling and their association with PH in
patients with COPD. In patients with COPD, we genotyped 7 SNPs in 6 candidate PH genes (NOS3, ACE, EDN1,
PTGIS, SLC6A4, VEGFA). We tested for association with right ventricular systolic pressure (RVSP), spirometry and
gas transfer, and hypoxemia.
Methods: In patients with COPD, we genotyped 7 SNPs in 6 candidate PH genes (NOS3, ACE, EDN1, PTGIS,
SLC6A4, VEGFA). We tested for association with right ventricular systolic pressure (RVSP), spirometry and gas
transfer, and hypoxemia.
Results: 580 COPD patients were recruited, 341 patients had a transthoracic echocardiogram, with RVSP measurable
in 278 patients (mean age 69 years, mean FEV1 50% predicted, mean RVSP 44 mmHg, median history of 50 pack-
years). Of the 7 tested SNPs, the NOS3-VNTR polymorphism was significantly associated with RVSP in a dose-
dependent fashion for the risk allele: mean RVSP for a/a and a/b genotypes were 52.0 and 46.6 mmHg respectively,
compared to 43.2 mmHg for b/b genotypes (P= 0.032). No associations were found between RVSP and other
polymorphisms. ACE II or ID genotypes were associated with a lower FEV1% predicted than the ACE DD genotype
(P= 0.028). The NOS3-298 TT genotype was associated with lower KCO % predicted than the NOS3-298 GG or GT
genotype (P= 0.031).
Conclusions: The NOS3-VNTR polymorphism was associated with RVSP in patients with COPD, supporting its
involvement in the pathogenesis of PH in COPD. ACE and NOS3 genotypes were associated with COPD disease
severity, but not with the presence of PH. Further study of these genes could lead to the development of prognostic
and screening tools for PH in COPD.
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Pulmonary hypertension (PH) is a serious complication
of chronic obstructive pulmonary disease (COPD) and
develops in 30% to 70% of patients with COPD, increas-
ing their morbidity and mortality [1]. PH is progressive
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reproduction in any medium, provided the orincreasing over time [2,3]. Understanding variations in
susceptibility to PH in patients with COPD could signifi-
cantly enhance diagnosis, risk stratification and therapy
for these patients.
Vascular remodelling is the main pathological feature
in PH and is mediated via vasoactive molecules [4].
Genes encoding these mediators contain genetic poly-
morphisms that potentially affect their function and
could influence PH in COPD [5-18]. Polymorphisms
exist in vasodilator (nitric oxide synthase (NOS3) [8,13],
prostacyclin synthase (PTGIS) [19]) and vasoconstrictor
(angiotensin converting enzyme (ACE) [17], endothelin-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lar endothelial growth factor (VEGFA) [20] genes.
We hypothesised that genetic variation in genes encod-
ing mediators acting on pulmonary vessels alters right
ventricular systolic pressure (RVSP) in patients with
COPD, even after adjustment for clinical factors asso-
ciated with elevated RVSP. Additionally, we hypothesised
that these polymorphisms are associated with COPD dis-
ease severity. We selected variants previously associated
with vascular disease, in vasoactive mediators of bio-
logical importance in pulmonary hypertension.
Methods
Participants
Patients with a thoracic physician’s diagnosis of COPD,
based on chronic airflow limitation not fully reversible
with bronchodilator [21], reduced gas transfer (KCO)
and/or emphysema on CT scan, were recruited from
thoracic clinics and wards of The Prince Charles Hos-
pital (TPCH). Patients with other major respiratory dis-
eases, including interstitial lung disease, lung cancer,
pneumonia, cystic fibrosis, bronchiectasis, pleural effu-
sion and lung surgery, were excluded. All participants
gave written informed consent. This study was approved
by the research ethics committees of TPCH (EC9865
and EC2108) and The University of Queensland (H372).
Clinical phenotyping
Participants completed a clinical questionnaire about
their lung disease, symptoms, smoking history and eth-
nicity. One pack-year of smoking was defined as the
equivalent of 20 cigarettes smoked per day for one year.
Chronic bronchitis was defined as a cough with sputum
production for at least 3 months in each of two consecu-
tive years [21].
Lung function tests
Participants had lung function tests at recruitment, dur-
ing their routine care at the hospital, whilst clinically
stable. Lung function testing consisted of spirometry and
single breath carbon monoxide diffusing capacity
(DLCO) and performed according to American Thoracic
Society/European Respiratory Society Taskforce (ATS/
ERS) standards [22-24]. Measurements were compared
to predicted values [25,26]. The lung function para-
meters FEV1, slow vital capacity (VC), FEV1/VC ratio
and KCO were used to characterise COPD.
Echocardiography
A subgroup of patients had a transthoracic echocardio-
gram performed as a routine part of their clinical care,
using standard techniques [27]. RVSP was calculated
using the simplified Bernoulli equation. The pressure
difference between the right ventricle and right atriumduring systole is reflected by the velocity of the tricus-
pid regurgitation (TR) signal. RVSP can be estimated
from right atrial pressure using the equation RVSP= 4
(VTR)
2 + RAP, where VTR is peak TR velocity (m/s) and
RAP is mean right atrial pressure (mmHg). The mean
RAP is estimated using inferior vena cava (IVC) size
and reactivity as per American Society of Echocardiog-
raphy (ASE) recommendations [28].
Arterial blood gases
Arterial blood gas (ABG) results were obtained from the
patients’ medical records. Arterial blood was drawn from
the radial artery while the patients breathed room air.
Genotyping
Genomic DNA was extracted from peripheral blood
using a modified salt extraction method [29]. Polymerase
chain reaction (PCR) was used to genotype two poly-
morphisms, PCR with restriction fragment length poly-
morphism (RFLP) was used for three polymorphisms,
and single base pair extension was used for one poly-
morphism (see Additional file 1: Table S1). PCR reac-
tions were performed in a final volume of 20 μl
containing 10 ng genomic DNA, 0.2 mM of dNTPs, and
0.25 μM of each of the forward and reverse primers. For
five polymorphisms, 0.5 U REDTaq DNA polymerase
(Sigma, Saint Louis, Missouri, USA) and 10x REDTaq
PCR reaction buffer were used. For the SLC6A4 poly-
morphism, 1.5 U HotStarTaq DNA polymerase (QIA-
GEN, Hilden, Germany) and 10x HotStar PCR reaction
buffer were used, together with 5x Q-Solution. The PCR
amplification was performed in a thermal cycler. Geno-
types were determined by agarose gel electrophoresis of
PCR products. Ethidium bromide was added to each gel
at 1 μg/ml final concentration. The stained bands were
visualised by the Molecular Imager FX (Bio-Rad,
Hercules, California, USA). To ensure reproducibility,
10% of the samples were chosen randomly and repeated
for each polymorphism; these genotypes were confirmed
by this repeated testing.
The EDN1 gene polymorphism was genotyped by sin-
gle base extension with alleles identified by direct mass
measurement of the analyte using the SEQUENOMTM
MassARRAYW system (MALDI-TOF mass spectrometry)
at the Australian Genome Research Facility.
Statistical methods
SPSS (Statistical Package for the Social Sciences) for
Windows Version 17.0 (SPSS Inc, Chicago Illinois, USA)
was used. Hardy-Weinberg equilibrium was calculated
using the χ2 test to compare expected vs observed geno-
type frequencies. Associations of genotypes with RVSP
or lung function were performed using ANOVA for
additive genotype models (AA vs AB vs BB), and t-tests
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vs BB) genotype models. Adjustment for clinical con-
founders was performed using multiple linear regression,
in which genotypes and clinical covariates (age, gender,
BMI, PaO2, FEV1% predicted, KCO % predicted) were
independent variables, and RVSP was the dependent
variable. Analyses were done for all available partici-
pants, and also with the subgroup of COPD patients
with FEV1/VC< 0.7. In all analyses, a two-tailed P value
of <0.05 was considered significant.
For the t-test analyses of RVSP using dominant or re-
cessive models, power calculations indicated that a total
of 190 participants with RVSP measurements were
required to detect a difference of 15% in mean RVSP in
the cohort, with 80% power (based on mean RVSP of
44 mmHg, SD 13 mmHg, P value of 0.05, and ratio of





Mean (SD) age at recruitment (yr) 68.1 (9.3)
Range 35.1–87.0
Median smoking history (pack years) 50
(IQR) (33.8-69.0)
Range 0.0-186.0
Chronic bronchitis present (% of total) 201 (35%)
Mean (SD) FEV1 (L) 1.2 (0.63)
Range 0.2-4.7
Mean (SD) FEV1% predicted 50 (21.8)
Range 7-129
Mean (SD) VC (L) 2.8 (0.92)
Range 0.9-6.4
Mean (SD) VC (L) % predicted 77.3 (17.8)
Range 28.5-132.3
Mean (SD) FEV1/VC ratio % 45 (15)
Range 7-80
Mean (SD) KCO (ml/min/mmHg/L) 2.5 (0.96)
Range 0.44-6.6
Mean (SD) KCO % predicted 58 (22.5)
Range 9.8-134.5
Mean (SD) RVSP (mmHg) 44.2 (12.7)
Range 16.0-94.0
Mean (SD) PaO2 (mmHg) 70.5 (11.6)
Range 35.0-99.0
Mean (SD) PaCO2 (mmHg) 41.3 (7.7)
Range 26.0-76.0
Mean (SD) BMI (kg/m2) 25.0 (5.5)
Range 13.0-46.1all variants studied, except the NOS3 VNTR which had a
lower ratio) (PS Power calculation program [30]). Power




580 patients with COPD were studied (Table 1); most
were Caucasian males (only two of Asian ethnicity), with
a mean age of 68 years. Chronic bronchitis was present
in 35% of patients. All were current or former smokers,
with the exception of six never smokers who neverthe-
less satisfied criteria for COPD. 514 patients (89%) had
moderate to severe airflow limitation (FEV1% predicted
< 80%), with mean FEV1 50% predicted. Gas transfer
(KCO) was measured in 97% (561/580) of patients, and












99 (36%) 26 (41%) 0.33
1.20 (0.55) 1.13 (0.50) 0.40
0.2-3.9 0.34-3.09
50 (20.8) 44.5 (18.1) 0.062
7-129 11.4-89.3
2.7 (0.83) 2.81 (0.87) 0.28
0.9-5.6 1.15-4.88
76.0 (17.4) 75.5 (16.6) 0.88
28.8-132.3 36.3-111.0
45 (14) 40.9 (13.5) 0.026
7-80 17.5-67.9
2.4 (0.97) 2.56 (0.97) 0.36
0.44-6.6 0.49-4.7
58 (23.4) 59.8 (22.4) 0.60
12.6-134.5 9.8-109.8
44.2 (12.7) Unable to
16.0-94.0 measure
69.4 (11.8) 71.7 (11.5) 0.23
35.0-99.0 53.0-95.0
41.6 (8.1) 40.8 (7.7) 0.49
27.0-76.0 26.0-62.0
24.9 (5.3) 26.0 (5.5) 0.14
13.5-44.0 15.9-46.1
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was 58%. ABG results were obtained for 271 patients
who also had a measureable RVSP, 81% of the patients
had an ABG within 12 months of their echocardiogram.Echocardiography
Echocardiography was performed in 341 of the 580
(59%) patients. RVSP was measurable in 278 of the 341
patients who had an echocardiogram (82% of total 341).
The demographic characteristics of patients who had
echocardiography did not differ significantly from those
of patients with no echocardiography. Echocardiography
was performed but no RVSP measurement was possible
in 63 patients either because there was no tricuspid re-
gurgitation or the echocardiogram was technically diffi-
cult and echo signals could not be obtained.
Demographic and disease characteristics were similar
between patients with and without measurable RVSP,
except for a lower FEV1/VC ratio in those without
measurable RVSP. Both these subgroups had similar
characteristics to the whole cohort (Table 1). RVSP
measurements ranged from 16 to 94 mmHg, 115
patients were within the normal range chosen for this
study (15-39 mmHg) and 163 patients (59%) had
RVSP≥ 40 mmHg [31].
Data on the left ventricular ejection fraction (EF), mi-
tral valve and aortic valve were collected for each patient.
13 patients had missing EF measurements and 6 patients
had missing information on both mitral and aortic valves.
A normal EF (>50%) was recorded for 275 (80% of 328)
of the patients (range 11% - 82%, mean (SD) 59% (12.2)).
60% (205 of 335) of the patients had a normal mitral
valve, with 123 (36%) having some degree of mitral regur-
gitation (of whom 38 had moderate to severe mitral re-
gurgitation), 5 (1.5%) having mitral stenosis (of whom 3
had moderate to severe mitral stenosis) and 2 (0.6%) hav-
ing both. A normal aortic valve was found in 48% (165 of
335) of the patients, 103 (30%) had aortic valve sclerosis,
54 (16%) had aortic regurgitation (of whom 14 had mod-
erate to severe aortic regurgitation) and 13 (3.8%) had
aortic stenosis (of whom 7 had moderate to severe aortic
stenosis).Genotypes
98.6% to 100% of all the patients were successfully geno-
typed by the PCR or PCR-RFLP methods, and the EDN1
polymorphism had a 95.7% success rate using the single
base extension method. The distribution of the geno-
types for 6 of the 7 polymorphisms were in Hardy-
Weinberg equilibrium (HWE), with the exception being
NOS3-Glu298Asp SNP which deviated from HWE
(P= 0.02).Association of genotypes with RVSP measurements
One-way ANOVA was used to test the relationship be-
tween genotype and RVSP (Table 2). There was a signifi-
cant association between RVSP and NOS3-VNTR SNP
genotypes (P= 0.032), with highest mean RVSP in
patients with 4aa genotype of the VNTR. There were no
statistically significant associations with RVSP for SNP
genotypes of other genes tested (VEGFA, ACE, SLC6A4,
PTGIS, NOS3-298 and EDN1). The distribution of geno-
types in the subgroup of COPD patients with a RVSP
measurement were in agreement with the HWE pre-
dicted frequencies except for EDN1 (P= 0.04).
When considering only those COPD patients with
FEV1/VC< 0.7 (n = 263), the NOS3-VNTR SNP geno-
type association remained statistically significant in a
t-test analysis (4bb, mean (SD) 43.5 mmHg (11.8),
n = 186 vs 4ab/4aa, mean (SD) 47.1 mmHg (14.6)
n = 77, P= 0.034).
Association of clinical factors with RVSP measurements
Clinical factors potentially confounding the association
of genotypes with RVSP include arterial PaO2, FEV1%
predicted, KCO % predicted and FEV1/VC ratio, all of
which showed weak inverse correlations with RVSP
(Table 3).
Association of genotypes with lung function impairment
To detect disease-modifying effects of the candidate
SNPs one-way ANOVA analyses were performed be-
tween genotypes and FEV1 (% predicted) and KCO (%
predicted). No significant associations were found
(Tables 4 and 5).
Linear regression modelling of associations with RVSP
measurements
Multiple linear regression modelling was used to test
whether genotypes associated with RVSP remained sig-
nificantly associated, when controlled for clinical factors.
Arterial PaO2 and KCO % predicted were significantly
associated with RVSP in all analyses (see Additional file
1: Table S2). The association with NOS3-VNTR, as
grouped genotypes 4aa + 4ab vs 4bb, remained signifi-
cantly associated with RVSP, even when controlling for
the clinical factors (see Additional file 1: Table S3).
Additional genetic modelling
Patients with the NOS3-VNTR 4aa or 4ab genotypes had
significantly higher RVSP levels than the NOS3-VNTR
4bb genotype (see Additional file 1: Table S3). There
were no other significant differences observed between
genotypes and RVSP when using dominant and recessive
genetic models. The ACE II or ID genotypes were asso-
ciated with a significantly lower FEV1% predicted than
the DD genotype (P= 0.028) (see Additional file 1: Table
Table 2 Association of genotypes with RVSP measurements in COPD patients with an RVSP measurement, using
ANOVA





VEGFA GG 123 42.8 12.0 0.24
GC 117 45.2 13.6
CC 38 46.0 12.1
Total 278 44.2 12.7
NOS3-VNTR 4bb 199 43.2 11.8 0.032
4ab 70 46.6 13.8
4aa 8 52.0 20.2
Total 277 44.3 12.7
ACE II 69 45.6 14.2 0.61
ID 139 44.0 12.5
DD 69 43.6 11.6
Total 277 44.3 12.7
SLC6A4 LL 90 42.7 12.6 0.43
LS 131 44.8 13.2
SS 53 45.1 11.3
Total 274 44.2 12.6
PTGIS CC 172 43.9 12.2 0.83
CA 90 45.0 13.6
AA 15 44.3 13.8
Total 277 44.3 12.7
NOS3-298 GG 120 44.4 12.6 0.83
GT 135 43.9 12.4
TT 22 45.6 15.7
Total 277 44.3 12.7
EDN1 GG 159 43.5 12.8 0.15
GT 83 46.0 12.8
TT 24 40.7 9.3
Total 266 44.0 12.6
Some samples could not be genotyped, making the totals less than 278.
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predicted. The NOS3-298 TT genotype was associated
with lower KCO % predicted than GG or GT genotypesTable 3 Correlation of clinical factors with RVSP in COPD
patients with an RVSP measurement
Clinical Factor Number Correlation
(r)
P value
PaO2 vs RVSP 222 −0.245 0.00023
PaCO2 vs RVSP 222 0.041 0.55
FEV1% predicted vs RVSP 278 −0.118 0.050
KCO percent predicted vs RVSP 268 −0.258 0.000019
Age at recruitment vs RVSP 278 0.117 0.050
Smoking history: pack years vs RVSP 278 −0.042 0.48
FEV1/VC ratio vs RVSP 278 −0.133 0.027
BMI vs RVSP 278 −0.115 0.055(P= 0.031) (see Additional file 1: Table S5). No other sig-
nificant differences were found between genotypes and
KCO % predicted.Discussion
Few previous studies have examined multiple poly-
morphisms in relation to PH associated with COPD.
In our study we examined seven SNPs in six candidate
genes which encode mediators that act on pulmonary
vessels. We tested whether these SNPs were associated
with RVSP, which is a measure of PH. We found that
patients with the NOS3-VNTR 4aa or 4ab genotype
had significantly higher RVSPs than those with the
NOS3-VNTR 4bb genotype. In contrast, a study of 42
COPD patients and 40 controls found that the NOS3-
VNTR 4bb genotype was associated with PH in COPD
[13]. The smaller number of patients in their study
Table 4 Association of genotype groups with FEV1%
predicted, using ANOVA





VEGFA GG 246 48.7 21.0 0.23
GC 256 50.6 22.7
CC 75 53.5 20.4
Total 577 21.7
NOS3-VNTR 4bb 414 50.0 22.3 0.80
4ab 148 51.0 20.6
4aa 15 47.7 17.7
Total 577 21.7
ACE II 142 49.6 20.9 0.09
ID 283 48.8 21.9
DD 153 53.6 22.2
Total 578 21.8
SLC6A4 LL 179 49.7 22.7 0.97
LS 285 50.2 21.2
SS 107 50.2 22.1
Total 571 21.8
PTGIS CC 336 50.0 21.0 0.77
CA 200 49.9 22.8
AA 42 52.4 23.1
Total 578 21.7
NOS3-298 GG 258 50.1 21.0 0.61
GT 276 50.9 22.8
TT 41 47.4 18.3
Total 575 21.7
EDN1 GG 322 50.0 22.4 0.77
GT 178 50.6 21.3
TT 42 47.9 19.1
Total 542 21.8
Some samples could not be genotyped, making the totals less than 580.
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are required to validate our findings.
There have been conflicting functional studies of the
NOS3-VNTR 4aa genotype and plasma nitrite and ni-
trate (NOx) levels. A study of 428 healthy Caucasian
members of 108 nuclear families found significantly
higher levels of plasma NOx associated with the 4aa
genotype compared to the 4bb and 4ab genotypes
[32]. However another study found that there was a
strong association between plasma NOx levels and the
NOS3-VNTR polymorphism in 413 healthy Japanese
subjects, the subjects with the 4aa genotype having
significantly lower NOx levels [33]. The discordant
results between these two studies may be due to eth-
nicity or methodological differences in measuring
NOx levels. The functional results from this second
study would support our finding of the 4aa genotype(with potentially lower nitric oxide levels and there-
fore less vasodilatation) being associated with higher
RVSP (higher vascular resistance). The exact func-
tional mechanisms of how the VNTR, or a nearby
SNP which is in linkage disequilibrium with it, affects
either nitric oxide or vascular remodelling, needs fur-
ther elucidation.
We identified a number of clinical factors as being sig-
nificantly associated with elevated RVSP on univariate
analysis. These factors are well-known clinical markers
of severity of COPD, and would be expected to correlate
with elevated RVSP, since PH is related to COPD sever-
ity [31]. The NOS3-VNTR polymorphism was signifi-
cantly associated with RVSP, and remained so when
controlling for these factors.
Considering potential links between COPD severity
and PH, we examined the effect of SNPs in relation to re-
spiratory function tests. Patients with the ACE II or ID
genotypes showed a statistically significantly lower
FEV1% predicted, albeit a clinically small difference, than
the ACE DD genotypes. Analysis of the other genetic
models for ACE genotypes did not show associations.
This is in contrast to a previous study of Caucasian Med-
iterraneans which found a higher frequency of ACE DD
genotypes in 74 male smokers with COPD than in 77
male smokers with normal lung function (odds ratio 2.2)
[34]. Additional studies are required to clarify this
relationship.
Patients with the NOS3-298 TT genotype had signifi-
cantly lower KCO than those with the GG or GT geno-
types. Sun and co-workers’ hypothesis [8] supports our
results in that the lower NO levels associated with the
TT genotype would potentially predispose those patients
to greater lung tissue damage from cigarette smoke
reflected in a reduced KCO.
Potential limitations of this study should be consid-
ered. Two of the SNPs showed minor deviation in
Hardy-Weinberg equilibrium, although these did not
show positive associations. The reason for the minor
deviation could include chance or differences in popu-
lation sampling; we had performed repeat genotyping
in 10% of samples and the results were concordant.
In some COPD patients, RVSP measurement was not
successful because of hyperinflated lungs causing a
large retrosternal window, or because the tricuspid
regurgitant jet was insufficient to enable calculation of
RVSP. Use of echo contrast may have increased the
yield of RVSP measurements in these cases. Given the
exploratory nature of this study of 7 SNPs and RVSP
in COPD, we did not correct for multiple compari-
sons, and the statistical significance of the results
should be considered in light of this. Even with this
relatively large cohort of patients, replication in other
cohorts is needed. Functional analysis of polymorphisms
Table 5 Association of genotype groups with KCO % predicted, in COPD patients with a KCO measurement, using
ANOVA





VEGFA GG 241 58.4 23.0 0.88
GC 244 57.7 21.8
CC 73 59.1 23.9
Total 558 22.6
NOS3-VNTR 4bb 401 58.1 22.9 0.36
4ab 142 59.1 21.5
4aa 15 50.3 24.5
Total 558 22.6
ACE II 136 60.3 24.9 0.42
ID 273 57.3 22.1
DD 150 57.6 21.2
Total 559 22.6
SLC6A4 LL 176 58.0 22.4 0.84
LS 275 58.7 22.8
SS 101 57.2 22.0
Total 552 22.5
PTGIS CC 327 58.5 21.4 0.11
CA 192 56.2 23.8
AA 40 64.3 25.0
Total 559 22.6
NOS3-298 GG 250 58.5 24.0 0.10
GT 265 58.9 21.7
TT 41 50.9 16.7
Total 556
EDN1 GG 310 57.5 22.4 0.17
GT 173 57.5 22.7
TT 40 64.6 24.5
Total 523 22.7
Some samples could not be genotyped, making the totals less than 580.
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of PH in COPD would be worthwhile in the future.Conclusions
This study has shown a significant association between
RVSP in COPD patients and the NOS3-VNTR 4aa or
4ab genotype. We also found associations between the
ACE II or ID genotypes and lower FEV1% predicted and
the NOS3-298 TT genotype and lower KCO % pre-
dicted. These results suggest that these polymorphisms
may influence disease phenotype in COPD patients.
Further study of these genes could lead to the develop-
ment of prognostic and screening tools for PH in
COPD, eventually leading to novel therapy targeting
these pathways.Additional files
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